1 with great interest. We wish to discuss the important role of multimodality imaging in the management of patients with stable coronary artery disease (CAD).
With the rising prevalence of CAD and the associated costs of health care, the optimal therapeutic strategy for patients with stable CAD has been discussed widely over the past decade. Most randomized clinical trials, such as the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) 2 and the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), 3 failed to show a reduction in mortality or the incidence of myocardial infarction with revascularization compared with optimal medical therapy. A newly published metaanalysis supports this finding. 4 However, in almost all these studies, randomi zation occurred after coronary angio graphy. Whether all patients need to undergo coronary angio graphy, and how to perform risk stratification by noninvasive testing remain unresolved.
Stress imaging with single-photon emission computed tomography (SPECT) provides substantial prognostic information in patients with stable CAD.
5 A large, retro spective study involving >10,000 patients assessed with SPECT showed that the bene fits of revascularization were confined to patients with ≥10% left ventricular ischemia. 6 Subsequently, the same research group expanded the results by retrospectively analyzing >13,000 patients, and found that those with a threshold of >10-15% ischemia without extensive scarring seem to benefit from revasculari zation. 7 Similarly, Zellweger et al. reported that, in 3,664 patients with 'silent' , asymptomatic ischemia, only those with ≥7.5% ischemia CORRESPONDENCE Importance of multimodality imaging to guide therapy in stable CAD Yuli Huang, Weiyi Mai and Yanxian Wu of the myocardium benefited from revascularization. 8 Moreover, Sorajja et al. observed that, in asymptomatic patients with diabeties mellitus, surgical revascularization was bene ficial only in patients determined by SPECT as being 'high risk' . 9 These observational studies highlight the importance of the degree of ischemia in risk stratification and management of patients with stable CAD.
Subgroup analyses of COURAGE 10 and BARI 2D
11 also showed that SPECT provides important information regarding prognosis in patients with stable CAD. However, determination of therapeutic strategy for these patients on the basis of the degree of ischemia on stress imaging has not been prospectively tested in randomized trials. Investigators in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) are currently randomly allocating patients with documented ischemia (>10% of left ventri cular mass) by noninvasive stress testing to optimal medical therapy or revascularization. Patients with left main CAD or nonobstructive CAD will be excluded by coronary CT assessment before randomization.
5, 12 We await the results of this trial, which might provide helpful information to optimize the management of patients with stable CAD.
In their Review, 1 van der Hoeven and colleagues discuss the combination of myocardial perfusion imaging and assessment of coronary artery anatomy by CT coronary angiography to refine the therapeutic strategy, reduce the risk of unnecessary invasive angiography, and maximize the effectiveness of revascularization. Co-registration of CT with SPECT or PET in clinical practice can allow comprehensive, noninvasive evalu ation of CAD, including both morphological and functional assessment. However, about half of the patients who underwent selective percutaneous coronary intervention for stable angina in either the UK in 2007 or the USA in 2004 did not receive a stress test to assess ischaemia. 13 Although no data on this issue are available in China to our knowledge, the situation is unlikely to be better than in the UK or USA. Given the high preva lence of CAD worldwide and the number of inappropriate revascularization procedures, we strongly advocate the comprehensive, noninvasive evaluation of CAD burden by multimo dality imaging to determine the appropriate therapeutic strategy.
